Bristol Myers Squibb’s (BMS) Opdualag™ (nivolumab and relatlimab-rmbw) has received FDA approval to treat unresectable or metastatic melanoma in patients who are at least 12 years old.

• Opdualag combines nivolumab, the active pharmaceutical ingredient (API) in BMS’s Opdivo®, with a first-in-class LAG-3-blocking antibody, Both APIs help to increase the body’s immune activity to fight cancer cells.
• In adults and pediatric patients who are at least 12 years old and weigh at least 40kg (88 pounds), the recommended dosing is 480mg nivolumab and 160mg relatlimab administered by intravenous infusion once every four weeks until disease progression or unacceptable toxicity occur. The recommended dosing has not been established for pediatric patients at least 12 years of age who weigh less than 40kg.
• Although launch plans are not yet available, Opdualag is anticipated to have a wholesale acquisition cost (WAC) of $27,389 per infusion.